1. known past laboratory-confirmed sars-cov-2 infection 2. positive sars-cov-2 rt pcr test at screening 3. seropositivity to sars-cov-2 at screening. 4. significant infection or other illness, including fever \> 37.8°c on the day prior to or day randomization 5. history of guillain-barré syndrome 6. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days) 7. history of allergy to any component of the vaccine 8. any history of angioedema 9. any history of anaphylaxis 10. current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and uterine cervical carcinoma in situ) 11. history of serious psychiatric condition likely to affect participation in the study 12. bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following im injections or venepuncture 13. suspected or known current alcohol or drug dependency 14. any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data 15. severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)

1. known past laboratory-confirmed sars-cov-2 infection 2. positive sars-cov-2 rt pcr test at screening 3. seropositivity to sars-cov-2 at screening. 4. significant infection or other illness, including fever \> 37.8°c on the day prior to or day randomization 5. history of guillain-barré syndrome 6. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days) 7. history of allergy to any component of the vaccine 8. any history of angioedema 9. any history of anaphylaxis 10. current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and uterine cervical carcinoma in situ) 11. history of serious psychiatric condition likely to affect participation in the study 12. bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following im injections or venepuncture 13. suspected or known current alcohol or drug dependency 14. any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data 15. severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)

known past laboratory-confirmed sars-cov-2 infection positive sars-cov-2 rt pcr test at screening seropositivity to sars-cov-2 at screening. significant infection or other illness, including fever > 37.8°c on the day prior to or day randomization history of guillain-barré syndrome any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days) history of allergy to any component of the vaccine any history of angioedema any history of anaphylaxis current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and uterine cervical carcinoma in situ) history of serious psychiatric condition likely to affect participation in the study bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following im injections or venepuncture suspected or known current alcohol or drug dependency any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)

known past laboratory-confirmed sars-cov-2 infection positive sars-cov-2 rt pcr test at screening seropositivity to sars-cov-2 at screening. significant infection or other illness, including fever > 37.8°c on the day prior to or day randomization history of guillain-barré syndrome any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days) history of allergy to any component of the vaccine any history of angioedema any history of anaphylaxis current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and uterine cervical carcinoma in situ) history of serious psychiatric condition likely to affect participation in the study bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following im injections or venepuncture suspected or known current alcohol or drug dependency any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)

1. known past laboratory-confirmed sars-cov-2 infection 2. positive sars-cov-2 rt pcr test at screening 3. seropositivity to sars-cov-2 at screening. 4. significant infection or other illness, including fever > 37.8°c on the day prior to or day randomization 5. history of guillain-barré syndrome 6. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days) 7. history of allergy to any component of the vaccine 8. any history of angioedema 9. any history of anaphylaxis 10. current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and uterine cervical carcinoma in situ) 11. history of serious psychiatric condition likely to affect participation in the study 12. bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following im injections or venepuncture 13. suspected or known current alcohol or drug dependency 14. any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data 15. severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)

1. known past laboratory-confirmed sars-cov-2 infection 2. positive sars-cov-2 rt pcr test at screening 3. seropositivity to sars-cov-2 at screening. 4. significant infection or other illness, including fever > 37.8°c on the day prior to or day randomization 5. history of guillain-barré syndrome 6. any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days) 7. history of allergy to any component of the vaccine 8. any history of angioedema 9. any history of anaphylaxis 10. current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and uterine cervical carcinoma in situ) 11. history of serious psychiatric condition likely to affect participation in the study 12. bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following im injections or venepuncture 13. suspected or known current alcohol or drug dependency 14. any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data 15. severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)